Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.

[1]  Amy R. Peck,et al.  Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms , 2016, Modern Pathology.

[2]  H. Rui,et al.  Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression. , 2016, Cell reports.

[3]  Chun Jimmie Ye,et al.  Parsing the Interferon Transcriptional Network and Its Disease Associations , 2016, Cell.

[4]  林雨樵.  Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity , 2015 .

[5]  M. Sadelain,et al.  Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. , 2015, Cancer cell.

[6]  Jeffrey W. Clark,et al.  Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.

[7]  L. Zitvogel,et al.  Type I interferons in anticancer immunity , 2015, Nature Reviews Immunology.

[8]  D. Fearon,et al.  T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.

[9]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[10]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[11]  Florian Klemm,et al.  Microenvironmental regulation of therapeutic response in cancer. , 2015, Trends in cell biology.

[12]  M. Delorenzi,et al.  Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.

[13]  H. Rui,et al.  The Paracrine Hormone for the GUCY2C Tumor Suppressor, Guanylin, Is Universally Lost in Colorectal Cancer , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[14]  K. Köhrer,et al.  Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity. , 2014, Immunity.

[15]  I. Xenarios,et al.  Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1. , 2014, Immunity.

[16]  J. Klein-Seetharaman,et al.  Oxidized Lipids Block Antigen Cross-Presentation by Dendritic Cells in Cancer , 2014, The Journal of Immunology.

[17]  D. Fearon.  The Carcinoma-Associated Fibroblast Expressing Fibroblast Activation Protein and Escape from Immune Surveillance , 2014, Cancer Immunology Research.

[18]  H. Rui,et al.  Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury , 2014, EMBO molecular medicine.

[19]  J. C. Love,et al.  In vivo discovery of immunotherapy targets in the tumour microenvironment , 2014, Nature.

[20]  B. Viollet,et al.  TIM-4 glycoprotein-mediated degradation of dying tumor cells by autophagy leads to reduced antigen presentation and increased immune tolerance. , 2013, Immunity.

[21]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[22]  G. Trinchieri,et al.  Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation. , 2013, The Journal of clinical investigation.

[23]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2013, Nature Medicine.

[24]  Chirayu Pankaj Goswami,et al.  PROGgene: gene expression based survival analysis web application for multiple cancers , 2013, Journal of Clinical Bioinformatics.

[25]  D. Baker,et al.  Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses , 2013, Oncogene.

[26]  Andriani Daskalaki,et al.  High-Throughput miRNA and mRNA Sequencing of Paired Colorectal Normal, Tumor and Metastasis Tissues and Bioinformatic Modeling of miRNA-1 Therapeutic Applications , 2013, PloS one.

[27]  S. Fuchs.  Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy. , 2013, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[28]  Simon Yu,et al.  INTERFEROME v2.0: an updated database of annotated interferon-regulated genes , 2012, Nucleic Acids Res..

[29]  H. Pircher,et al.  CD8 T Cell Priming in the Presence of IFN-α Renders CTLs with Improved Responsiveness to Homeostatic Cytokines and Recall Antigens: Important Traits for Adoptive T Cell Therapy , 2012, The Journal of Immunology.

[30]  Paul J Hertzog,et al.  Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape , 2012, Nature Medicine.

[31]  H. Abken,et al.  CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. , 2012, Trends in molecular medicine.

[32]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[33]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[34]  R. Schreiber,et al.  Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. , 2012, Cell host & microbe.

[35]  R. Lothe,et al.  ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis , 2012, Gut.

[36]  D. Baker,et al.  Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis. , 2011, Blood.

[37]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[38]  R. Schreiber,et al.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.

[39]  G. A. Stringer,et al.  Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Ju-Seog Lee,et al.  LIN28B promotes colon cancer progression and metastasis. , 2011, Cancer research.

[41]  D. Baker,et al.  Pathogen Recognition Receptor Signaling Accelerates Phosphorylation-Dependent Degradation of IFNAR1 , 2011, PLoS pathogens.

[42]  H. Rui,et al.  Inflammatory signaling compromises cell responses to interferon alpha , 2011, Oncogene.

[43]  D. Baker,et al.  Role of p38 Protein Kinase in the Ligand-independent Ubiquitination and Down-regulation of the IFNAR1 Chain of Type I Interferon Receptor* , 2011, The Journal of Biological Chemistry.

[44]  M. Wong,et al.  Fusion between Intestinal epithelial cells and macrophages in a cancer context results in nuclear reprogramming. , 2011, Cancer research.

[45]  A. Hatzigeorgiou,et al.  In vivo profiling of hypoxic gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection. , 2011, Cancer research.

[46]  J. Prieto,et al.  Effects of IFN‐α as a signal‐3 cytokine on human naïve and antigen‐experienced CD8+ T cells , 2010, European journal of immunology.

[47]  G. Trinchieri,et al.  Type I interferon: friend or foe? , 2010, The Journal of experimental medicine.

[48]  Eytan Domany,et al.  Association of survival and disease progression with chromosomal instability: A genomic exploration of colorectal cancer , 2009, Proceedings of the National Academy of Sciences.

[49]  R. Hamanaka,et al.  Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor. , 2009, Cell host & microbe.

[50]  M. Colonna,et al.  DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors , 2008, The Journal of experimental medicine.

[51]  E. Unanue,et al.  Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity , 2008, Science.

[52]  J. Talmadge,et al.  Inflammatory cell infiltration of tumors: Jekyll or Hyde , 2007, Cancer and Metastasis Reviews.

[53]  Michael Y. Gerner,et al.  Signal 3 Availability Limits the CD8 T Cell Response to a Solid Tumor1 , 2007, The Journal of Immunology.

[54]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[55]  Marie Koschella,et al.  Cutting Edge: CD8 T Cells Specific for Lymphocytic Choriomeningitis Virus Require Type I IFN Receptor for Clonal Expansion1 , 2006, The Journal of Immunology.

[56]  J. Sprent,et al.  Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection , 2005, The Journal of experimental medicine.

[57]  Hallgeir Rui,et al.  Ultrahigh density microarrays of solid samples , 2005, Nature Methods.

[58]  L. Platanias.  Mechanisms of type-I- and type-II-interferon-mediated signalling , 2005, Nature Reviews Immunology.

[59]  J. Curtsinger,et al.  Cutting Edge: Type I IFNs Provide a Third Signal to CD8 T Cells to Stimulate Clonal Expansion and Differentiation1 , 2005, The Journal of Immunology.

[60]  H. Ohtani,et al.  Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis , 2004, British Journal of Cancer.

[61]  S. Fuchs,et al.  SCFHOS ubiquitin ligase mediates the ligand‐induced down‐regulation of the interferon‐α receptor , 2003 .

[62]  D. Tough,et al.  Links between innate and adaptive immunity via type I interferon. , 2002, Current opinion in immunology.

[63]  M. Lotze,et al.  IFN-α-Expressing Tumor Cells Enhance Generation and Promote Survival of Tumor-Specific CTLs , 2000, The Journal of Immunology.

[64]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[65]  K. Hellström,et al.  Cellular and Humoral immunity to Different Types of Human Neoplasms , 1968, Nature.

[66]  F. Belardelli,et al.  IFN-alpha in the generation of dendritic cells for cancer immunotherapy. , 2009, Handbook of experimental pharmacology.

[67]  G. Schreiber,et al.  The receptor of the type I interferon family. , 2007, Current topics in microbiology and immunology.

[68]  S. Fuchs,et al.  SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. , 2003, The EMBO journal.

[69]  M. Lotze,et al.  IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. , 2000, Journal of immunology.